Salmefamol

Salmefamol
Clinical data
Other namesAH-3923; AHR-3929; 1-(4-hydroxy-3-(hydroxymethyl)phenyl)-2-(4-methoxy-α-methylphenethylamino)ethanol
Routes of
administration		Inhalation, intravenous[1]
Drug classBronchodilator; β-Adrenergic receptor agonist
Identifiers
  • 4-[1-hydroxy-2-[1-(4-methoxyphenyl)propan-2-ylamino]ethyl]-2-(hydroxymethyl)phenol
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC19H25NO4
Molar mass331.412 g·mol−1
3D model (JSmol)
  • CC(CC1=CC=C(C=C1)OC)NCC(C2=CC(=C(C=C2)O)CO)O
  • InChI=1S/C19H25NO4/c1-13(9-14-3-6-17(24-2)7-4-14)20-11-19(23)15-5-8-18(22)16(10-15)12-21/h3-8,10,13,19-23H,9,11-12H2,1-2H3
  • Key:VPMWDFRZSIMDKW-UHFFFAOYSA-N

Salmefamol (INNTooltip International Nonproprietary Name, BANTooltip British Approved Name; developmental code name AH-3923) is a drug of the phenethylamine and amphetamine families described as a bronchodilator which was never marketed.[2] It is a β-adrenergic receptor agonist with some selectivity for the β2-adrenergic receptor[3][4] and has been described as a "sister compound" to salbutamol.[5] However, the drug is more potent (1.5-fold), longer-acting (6 hours), and more lipophilic in comparison to salbutamol.[6][1] It was intended for inhalational or intravenous administration.[1] Salmefamol was first described in the literature by 1968.[2]

References

  1. ^ a b c Patrick GL (2017). An Introduction to Medicinal Chemistry. Oxford University Press. p. 665. ISBN 978-0-19-874969-1. Retrieved 17 October 2024.
  2. ^ a b Elks J (2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer US. p. 1089. ISBN 978-1-4757-2085-3. Retrieved 17 October 2024.
  3. ^ Labrid C, Rocher I, Guery O (November 1989). "Structure-activity relationships as a response to the pharmacological differences in beta-receptor ligands". American Journal of Hypertension. 2 (11 Pt 2): 245S – 251S. doi:10.1093/ajh/2.11.245s. PMID 2573372.
  4. ^ Leclerc G, Rouot B, Velly J, Schwartz J (1981). "β-Adrenergic receptor subtypes". Trends in Pharmacological Sciences. 2. Elsevier BV: 18–20. doi:10.1016/0165-6147(81)90248-0. ISSN 0165-6147.
  5. ^ Clayden J, Greeves N, Warren S (2012). Organic Chemistry. OUP Oxford. p. 530. ISBN 978-0-19-927029-3. Retrieved 17 October 2024.
  6. ^ Kummer F (2012). Treatment of Asthma: The long-acting beta-2-agonists. Springer Vienna. p. 38. ISBN 978-3-7091-7513-2. Retrieved 17 October 2024.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.